J. Michael Ellis

Statistics

Publications

Citations

1.6K

H-Index

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of North Carolina at Chapel Hill

Bristol-Myers Squibb (Switzerland)

Pfizer (United States)

Bristol-Myers Squibb (United States)

J. Michael Ellis is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, medicinal chemistry, and chemistry.

ORCID

Publications per year

1994–2022

Publications

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Matthew Fell, Christian Mirescu, Kallol Basu et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 337 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of a Novel cGAMP Competitive Ligand of the Inactive Form of STING

Tony Siu, Michael D. Altman, Gretchen A. Baltus et al. · ACS Medicinal Chemistry Letters · 2018 · 172 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Quaternary Charge-Transfer Complex Enables Photoenzymatic Intermolecular Hydroalkylation of Olefins

Claire G. Page, Simon J. Cooper, Jacob S. DeHovitz et al. · Journal of the American Chemical Society · 2020 · 156 citations · Full text

Natural Sciences, Biochemistry, Chemistry +17

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Marco A. S. Baptista, Kalpana Merchant, Ted Barrett et al. · Science Translational Medicine · 2020 · 130 citations

Medicine, Pharmacology, Pharmacotherapy +9

Intermolecular Crossed [2 + 2] Cycloaddition Promoted by Visible-Light Triplet Photosensitization: Expedient Access to Polysubstituted 2-Oxaspiro[3.3]heptanes

Philip R. D. Murray, Willem M. M. Bussink, Geraint H. M. Davies et al. · Journal of the American Chemical Society · 2021 · 88 citations

Natural Sciences, Chemistry, Medicinal Chemistry +17

1–5 of 22